• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

硝苯地平、维拉帕米和环孢素A在儿童体内的药代动力学

Nifedipine, verapamil and cyclosporin A pharmacokinetics in children.

作者信息

Ogborn M R, Crocker J F, Grimm P C

机构信息

Department of Paediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.

出版信息

Pediatr Nephrol. 1989 Jul;3(3):314-6. doi: 10.1007/BF00858540.

DOI:10.1007/BF00858540
PMID:2702114
Abstract

We report two paediatric renal transplant patients in whom interaction with the calcium channel blocking agent verapamil resulted in reduced cyclosporin A (CyA) elimination. Prior therapy with another calcium channel blocking agent, nifedipine, did not affect CyA pharmacokinetics. We speculate that verapamil reduced CyA elimination in children via an effect upon the microsomal oxidase system that is independent of calcium channel activity.

摘要

我们报告了两名小儿肾移植患者,他们与钙通道阻滞剂维拉帕米相互作用后,环孢素A(CyA)的消除减少。先前使用另一种钙通道阻滞剂硝苯地平治疗时,并未影响CyA的药代动力学。我们推测,维拉帕米通过对微粒体氧化酶系统产生作用,从而减少儿童体内CyA的消除,这种作用独立于钙通道活性。

相似文献

1
Nifedipine, verapamil and cyclosporin A pharmacokinetics in children.硝苯地平、维拉帕米和环孢素A在儿童体内的药代动力学
Pediatr Nephrol. 1989 Jul;3(3):314-6. doi: 10.1007/BF00858540.
2
The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients.钙通道阻滞剂维拉帕米和硝苯地平与环孢素A在小儿肾移植患者中的相互作用。
Pediatr Nephrol. 1994 Aug;8(4):408-11. doi: 10.1007/BF00856514.
3
The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients.钙通道阻滞剂对肾移植受者中环孢素及其代谢物的影响。
Ther Drug Monit. 1990 Jul;12(4):321-8.
4
Cyclosporin-verapamil interaction.环孢素-维拉帕米相互作用。
Br J Clin Pharmacol. 1988 Mar;25(3):402-3. doi: 10.1111/j.1365-2125.1988.tb03321.x.
5
Evaluation of cyclosporin-verapamil interaction, with observations on parent cyclosporin and metabolites.环孢素与维拉帕米相互作用的评估,以及对母体环孢素及其代谢物的观察。
Clin Chem. 1988 Oct;34(10):2151.
6
The effect of calcium channel blockers on the cyclosporine dose requirement in renal transplant recipients.钙通道阻滞剂对肾移植受者环孢素剂量需求的影响。
Ren Fail. 1990;12(2):89-92. doi: 10.3109/08860229009087123.
7
Update on calcium-channel blocking agents.钙通道阻滞剂的最新进展。
Clin Pharm. 1983 Sep-Oct;2(5):403-16.
8
In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II).
Cancer Res. 1989 Jun 1;49(11):2844-50.
9
Calcium-channel blocking agents.钙通道阻滞剂
Clin Pharm. 1982 Jan-Feb;1(1):17-33.
10
[Calcium antagonists in the treatment of nephrogenic hypertension].[钙拮抗剂治疗肾性高血压]
Klin Med (Mosk). 1990 Aug;68(8):52-6.

引用本文的文献

1
Evaluation of drug interaction between cyclosporine and lercanidipine: a descriptive study.环孢素与乐卡地平药物相互作用的评价:一项描述性研究。
Eur J Hosp Pharm. 2024 Oct 25;31(6):560-563. doi: 10.1136/ejhpharm-2023-003757.
2
The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients.钙通道阻滞剂维拉帕米和硝苯地平与环孢素A在小儿肾移植患者中的相互作用。
Pediatr Nephrol. 1994 Aug;8(4):408-11. doi: 10.1007/BF00856514.
3
Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents.

本文引用的文献

1
The first pass metabolism of nifedipine in man.硝苯地平在人体中的首过代谢。
Br J Clin Pharmacol. 1984 Dec;18(6):951-4. doi: 10.1111/j.1365-2125.1984.tb02569.x.
2
Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil.钙通道阻滞剂地尔硫䓬和维拉帕米对肝微粒体药物代谢的抑制作用。
Biochem Pharmacol. 1985 Jul 15;34(14):2549-53. doi: 10.1016/0006-2952(85)90541-6.
3
Cyclosporine A: a clinical evaluation of drug interactions.
Transplant Proc. 1986 Dec;18(6 Suppl 5):50-5.
小儿高血压的药物治疗。对现有药物的疗效、安全性及剂量指南的全面综述。
Drugs. 1994 Dec;48(6):868-87. doi: 10.2165/00003495-199448060-00004.
4
Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.硝苯地平、维拉帕米和地尔硫䓬治疗期间安替比林和吲哚菁绿动力学的变化。
Clin Pharmacol Ther. 1986 Aug;40(2):239-42. doi: 10.1038/clpt.1986.169.
5
The effect of verapamil on cellular uptake, organ distribution, and pharmacology of cyclosporine.维拉帕米对环孢素细胞摄取、器官分布及药理学的影响。
Transplantation. 1987 Sep;44(3):395-401. doi: 10.1097/00007890-198709000-00014.
6
Selective inhibitory effects of nifedipine and verapamil on oxidative metabolism: effects on theophylline.硝苯地平和维拉帕米对氧化代谢的选择性抑制作用:对茶碱的影响。
Br J Clin Pharmacol. 1988 Mar;25(3):397-400. doi: 10.1111/j.1365-2125.1988.tb03319.x.
7
Cyclosporine: structure, pharmacokinetics, and therapeutic drug monitoring.环孢素:结构、药代动力学及治疗药物监测
Crit Rev Clin Lab Sci. 1987;25(4):275-311. doi: 10.3109/10408368709105886.
8
The effect of verapamil in reducing the severity of acute tubular necrosis in canine renal autotransplants.维拉帕米对减轻犬肾自体移植中急性肾小管坏死严重程度的作用。
Transplantation. 1987 Sep;44(3):355-7. doi: 10.1097/00007890-198709000-00006.
9
Cyclosporin-verapamil interaction.环孢素-维拉帕米相互作用。
Br J Clin Pharmacol. 1988 Mar;25(3):402-3. doi: 10.1111/j.1365-2125.1988.tb03321.x.
10
Cyclosporin A in paediatric kidney transplantation.
Pediatr Nephrol. 1987 Apr;1(2):125-30. doi: 10.1007/BF00849281.